Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: Implications for normal development and disease

Cell Death and Differentiation

Volumn 15, Issue 7, 2008, Pages 1178-1186

  Butts, B D ^a   Houde, C ^a   Mehmet, H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; GLUTAMIC ACID; MYELIN; MYELIN ASSOCIATED GLYCOPROTEIN; REACTIVE OXYGEN METABOLITE; TRANSFERRIN;

ALZHEIMER DISEASE; APOPTOSIS; CELL FUNCTION; CELL GROWTH; CELL LINEAGE; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; ENVIRONMENTAL FACTOR; ENVIRONMENTAL STRESS; GENE EXPRESSION; HUMAN; MULTIPLE SCLEROSIS; MYELINATION; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; WHITE MATTER;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BRAIN DISEASES; CELL DIFFERENTIATION; CELL LINEAGE; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; GLUTAMIC ACID; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; REACTIVE OXYGEN SPECIES; SCHIZOPHRENIA;

EID: 45449108428     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2008.70     Document Type: Review

References (127)

1. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407 770-776.
2. Wang J, Lenardo MJ. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J Cell Sci 2000; 113 (Part 5): 753-757.
3. Yoshida H, Kong YY, Yushida R, Elia AJ, Hakem A, Hakem R et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998; 94: 739-750.
4. Barres BA, Raff MC. Axonal control of oligodendrocyte development. J Cell Biol 1999; 147: 1123-1128.
5. Kaplan MR, Mayer-Franke A, Lambert S, Bennett V, Duncan ID, Levinson SR et al. Induction of sodium channel clustering by oligodendrocytes. Nature 1997; 386: 724-728.
6. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science 1997; 277: 1684-1687.
7. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 1996; 16: 5095-5105.
8. Simons M, Trajkovic K. Neuron-glia communication in the control of oligodendrocyte function and myelin biogenesis. J Cell Sci 2006; 119: 4381-4389.
9. Pfeiffer SE, Warrington AE, Bansal R. The oligodendrocyte and its many cellular processes. Trends Cell Biol 1993; 3: 191-197.
10. Nicolay DJ, Doucette JR, Nazaralii AJ. Transcriptional control of oligodendrogenesis. Glia 2007; 55: 1287-1299.
11. Bansal R, Stefansson K, Pfeiffer SE. Proligodendroblast antigen (POA), a developmental antigen expressed by A007/O4-positive oligodendrocyte progenitors prior to the appearance of sulfatide and galactocerebroside. J Neurochem 1992; 58: 2221-2229.
12. Wang S, Sdrulla AD, diSibio G, Bush G, Nofziger D, Hicks C et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron 1998; 21: 63-75.
13. Dugas JC, Ibrahim A, Barres BA. A crucial role for p57(Kip2) in the intracellular timer that controls oligodendrocyte differentiation. J Neurosci 2007; 27: 6185-6196.
14. Lathia JD, Rao MS, Mattson MP, Ffrench-Constant C. The microenvironment of the embryonic neural stem cell: Lessons from adult niches? Dev Dyn 2007; 236: 3267-3282.
15. Doetsch F. The glial identity of neural stem cells. Nat Neurosci 2003; 6: 1127-1134.
16. Bhat NR, Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: Role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. J Neurochem 1999; 72: 112-119.
17. Nicholas RS, Stevens S, Wing MG, Compston DA. Microglia-derived IGF-2 prevents TNF alpha induced death of mature oligodendrocytes in vitro. J Neuroimmunol 2002; 124: 36-44.
18. Pirianov G, Jesurasa A, Mehmet H. Developmentally regulated changes in c-Jun N-terminal kinase signalling determine the apoptotic response of oligodendrocyte lineage cells. Cell Death Diff 2006; 13: 531-533.
19. Scurlock B, Dawson G. Differential responses of oligodendrocytes to tumor necrosis factor and other pro-apoptotic agents: Role of ceramide in apoptosis. J Neurosci Res 1999; 55: 514-522.
20. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990; 5: 603-614.
21. Bansal R, Pfeiffer SE. Regulation of oligodendrocyte differentiation by fibroblast growth factors. Adv Exp Med Biol 1997; 429: 69-77.
22. Zeger M, Popken G, Zhang JH, Xuan SH, Lu QR, Schwab MH et al. Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination. Glia 2007; 55: 400-411.
23. Talbott JF, Cao Q, Bertram J, Nkansah M, Benton RL, Lavik E et al. CNTF promotes the survival and differentiation of adult spinal cord-derived oligodendrocyte precursor cells in vitro but fails to promote remyelination in vivo. Exp Neurol 2007; 204: 485-489.
24. Jones SA, Jolson DM, Cute KK, Mariash CN, Anderson GW. Trilodothyronine is a survival factor for developing oligodendrocytes. Mol Cell Endocrinol 2003; 199: 49-60.
25. Baron W, Colognato H, Ffrench-Constant C. Integrin-growth factor interactions, as regulators of oligodendroglial development and function. Glia 2005; 49: 467-479.
26. Colognato H, Baron W, Avellana-Adalid V, Relvas JB, Baron-Van Evercooren A, Georges-Labouesse E et al. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat Cell Biol 2002; 4: 833-641.
27. Frost EE, Buttery PC, Milner R, Ffrench-Constant C. Integrins mediate a neuronal survival signal for oligodendrocytes. Curr Biol 1999; 9: 1251-1254.
28. Dupree JL, Girault JA, Popko B. Mice deficient in myelin galactolipids exhibit dramatic alterations in node of ranvier structure and paranodin distribution. J Neurochem 1999; 73: S156.
29. Lalive PH, Paglinawan R, Biollaz G, Kappos EA, Leone DP, Malipiero U et al. TGF-beta-treated microglia induce oligodendrocyte precursor cell chemotaxis through the HGF-c-Met pathway. Eur J Immunol 2005; 35: 727-737.
30. Yan H, Rivkees SA. Hepatocyte growth factor stimulates the proliferation and migration of oligodendrocyte precursor cells. J Neurosci Res 2002; 69: 597-606.
31. Levine JM, Reynolds R, Fawcett JW. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001; 24: 39-47.
32. Tang DG, Tokumoto YM, Raff MC. Long-term culture of purified postnatal oligodendrocyte precursor cells. Evidence for an intrinsic maturation program that plays out over months. J Cell Biol 2000; 148: 971-9B4.
33. Wren D, Wolswijk G, Noble M. In vitro analysis of the origin and maintenance of O-2Aadult progenitor cells. J Cell Biol 1992; 116: 167-176.
34. Dawson MR, Levine JM, Reynolds R. NG2-expressing cells in the central nervous system: Are they oligodendroglial progenitors? J Neurosci Res 2000; 61: 471-479.
35. Dawson MR, Polito A, Levine JM, Reynolds R. NG2-expressing glial progenitor cells: An abundant and widespread population of cycling cells in the adult rat CNS. Mol Cell Neurosci 2003; 24: 476-488.
36. Kondo T, Raff M. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 2000; 289: 1754-1757.
37. Hertz L, Dringen R, Schousboe A, Robinson SR. Astrocytes: Glutamate producers for neurons. J Neurosci Res 1999; 57: 417-428.
38. Wosik K, Ruffini F, Almazan G, Olivier A, Nalbantoglu J, Antel JP. Resistance of human adult oligodendrocytes to AMPA/kainate receptor-mediated glutamate injury. Brain 2004; 127: 2636-2648.
39. Salter MG, Fern R. NMDA receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 2005; 438 1167-1171.
40. Karadottir R, Cavelier P, Bergersen LH, Attwell D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005; 438: 1162-1166.
41. Deng WB, Wang H, Rosenberg PA, Volpe JJ, Jensen FE. Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. Proc Natl Acad Sci USA 2004; 101: 7751-7756.
42. Domercq M, Matute C. Expression of glutamate transporters in the adult bovine corpus callosum. Brain Res Mol Brain Res 1999; 67: 296-302.
43. Oka A, Belliveau MJ, Rosenberg PA, Volpe JJ. Vulnerability of oligodendroglia to glutamate: Pharmacology, mechanisms, and prevention. J Neurosci 1993; 13: 1441-1453.
44. Matute C, Sanchez-Gomez MV, Martinez-Millan L, Miledi R. Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 1997; 94: 8830-8835.
45. Yoshioka A, Bacskai B, Pleasure D. Pathophysiology of oligodendroglial excitotoxicity. J Neurosci Res 1996; 46: 427-437.
46. Matute C, Domercq M, Sanchez-Gomez MV. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006; 53: 212-224.
47. Lawrence MS, Ho DY, Sun GH, Steinberg GK, Sapolsky RM. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J Neurosci 1996; 16: 486-496.
48. Sanchez-Gomez MV, Alberdi E, Ibarretxe G, Torre I, Matute C. Caspase-dependent and caspase-independent oligodendrocyte death mediated by AMPA and kainate receptors. J Neurosci 2003; 23: 9519-9528.
49. Ness JK, Scaduto RC, Wood TL. IGF-I prevents glutamate-mediated Bax translocation and cytochrome C release in O4(+) oligodendrocyte progenitors. Glia 2004; 46: 183-194.
50. Burnashev N. Calcium permeability of glutamate-gated channels in the central nervous system. Curr Opin Neurobiol 1996; 6: 311-317.
51. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu Rev Neurosci 1994; 17: 31-108.
52. Baimbridge KG, Celio MR, Rogers JH. Calcium-binding proteins in the nervous system. Trends Neurosci 1992; 15: 303-308.
53. Raha S. Robinson BH. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem Sci 2000; 25: 502-508.
54. Baud O, Haynes RF, Wang H, Folkerth RD, Li JR, Volpe JJ et al. Developmental upregulation of MnSOD in rat oligodendrocytes confers protection against oxidative injury. Eur J Neurosci 2004; 20 29-40.
55. Baud O, Greene AE, Li J, Wang H, Volpe JJ, Rosenberg PA. Glutathione peroxidase-catalase cooperativity is required for resistance to hydrogen peroxide by mature rat oligodendrocytes. J Neurosci 2004; 24 1531-1540.
56. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257: 163-173.
57. Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999; 274: 11455-11458.
58. 2+ homeostasis. Neurosci Res 2000; 37: 227-236.
59. Hemdan S, Almazan G. Deficient peroxide detoxification underlies the susceptibility of oligodendrocyte progenitors to dopamine toxicity. Neuropharmacology 2007; 52: 1385-1395.
60. 2-induced oligodendrocyte cell death: Role of glutathione, mitogen-activated protein kinases and caspase 3. J Neurochem 2004; 90: 392-404.
61. Khorchid A, Fragoso G, Shore G, Almazan G. Catecholamine-induced oligodendrocyte cell death in culture is developmentally regulated and involves free radical generation and differential activation of caspase 3. Glia 2002; 40: 283-299.
62. Levine SM, Chakrabarty A. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis. Ann NY Acad Sci 2004; 1012: 252-266.
63. Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia 1996; 17: 83-93.
64. Bartzokis G. Age-related myelin breakdown: A developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25: 5-18.
65. Blomgren K, Hagberg H. Free radicals, mitochondria, and hypoxia-ischemia in the developing brain. Free Rad Biol Med 2006; 40: 388-397.
66. Martin LJ, Al Abdulla NA, Bambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C. Nueurodegeneiation in excitotoxicity, global cerebral ischemia, and target deprivation: A perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998; 46: 281-309.
67. Hamrick SE, Miller SP, Leonard C, Glidden DV, Goldstein R, Ramaswanny V et al. Trends in severe brain injury and neurodevelopmental outcome in premature newborn infants: The role of cystic periventricular leukomalacia. J Pediatr 2004; 145: 593-599.
68. Ajayi-Obe M, Saeed N, Cowan FM, Rutherford MA, Edwards AD. Reduced development of cerebral cortex in extremely preterm infants. Lancet 2000; 356: 1162-1163.
69. Inder TE, Huppi PS, Warfield S, Kikinis R, Zientara GP, Barnes PD et al. Periventricular white matter injury in the premature infant is followed by reduced cerebral cortical gray matter volume at term. Ann Neurol 1999; 46: 755-760.
70. Maalouf EF, Duggan PJ, Rutherford MA, Counsell SJ, Fletcher AM, Battin M et al. Magnetic resonance imaging of the brain in a cohort of extremely preterm infants. J Pediatr 1999; 135: 331-357.
71. Hack M, Taylor HG, Drotar D, Schluchter M, Cartar L, Andreias L et al. Chronic conditions, functional limitations, and special health care needs of school-aged children born with extremely low-birth-weight in the 1990s. JAMA 2005; 294: 318-325.
72. Miller SP, Ferrioro DM, Leonard C, Piecuch R, Glidden DV, Partridge JC et al. Early brain injury in premature newborns detected with magnetic resonance imaging is associated with adverse early neurodevelopmental outcome. J Pediatr 2005; 147: 609-616.
73. Litt J, Taylor HG, Klein N, Hack M. Learning disabilities in children with very low birthweight: Prevalence, neuropsychological correlates, and educational interventions. J Learn Disabil 2005; 38: 130-141.
74. Back SA. Volpe JJ. Cellular and molecular pathogenesis of periventricular white matter injury. Ment Retard Dev Disabil Res Rev 1997; 3: 96-107.
75. Back SA, Luo NL, Borenstein NS, Levine JM, Volpe JJ, Kinney HC. Late oligodendrocyte progenitors coincide wth the developmental window of vulnerability for human perinatal white matter injury. J Neurosci 2001; 21: 1302-1312.
76. Back SA, Riddle A, McClure MM. Maturation-dependent vulnerability of perinatal white matter in premature birth. Stroke 2007; 38: 724-730.
77. Craig A, Ling Luo N, Beardsley DJ. Wingate-Pearse N, Walker DW, Hohimer AR et al. Quantitative analysis of perinatal rodent oligodendrocyte lineage progression and its correlation with human. Exp Neurol 2003; 181: 231-240.
78. Back SA, Han BH, Luo NL, Chricton CA, Xanthoudakis S, Tam J et al. Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci 2002; 22: 455-465.
79. Haynes RL, Folkerth RD, Keefe RJ, Sung I, Swzeda LI, Rosenberg PA et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol 2003; 62: 441-450.
80. Back SA, Rivkees SA. Emerging concepts in periventricular white matter injury. Semin Perinatol 2004; 28: 405-414.
81. Matute C, Alberdi E, Domercq M, Sanchez-Gomez MV, Perez-Samartin A, Rodriguez-Antiguedad A et al. Excitotoxic damage to white matter. J Anat 2007; 210: 693-702.
82. Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000; 20: 9235-9241.
83. Piani D, Fontana A. Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 1994; 152: 3578-3585.
84. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 1989; 2: 1547-1558.
85. Duggan PJ, Maalouf EF, Watts TL, Sullivan MH, Counsel SJ, Allsop J et al. Intrauterine T-cell activation and increased proinflammatory cytokine concentrations in preterm infants with cerebral lesions. Lancet 2001; 358: 1699-1700.
86. Grether JK, Nelson KB. Maternal infection and cerebral palsy in infants of normal birth weight. JAMA 1997; 278: 207-211.
87. Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177: 19-26.
88. Nelson KB, Grether JK. Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. Am J Obstet Gynecol 1998; 179: 507-513.
89. Hagberg H, Peebles D, Mallard C. Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults. Ment Retard Dev Disabil Res Rev 2002; 8: 30-38.
90. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42: 1-8.
91. Nelson KB, Grether JK, Dambrosia JM, Walsh E, Kohler S, Satyanarayana G et al. Neonatal cytokines and cerebral palsy in very preterm infants. Pediatr Res 2003; 53: 600-607.
92. Grether JK, Nelson KB, Walsh E, Willoughby RE, Redline RW. Intrauterine exposure to infection and risk of cerebral palsy in very preterm infants. Arch Pediatr Adolesc Med 2003; 157: 26-32.
93. Dammann O, Leviton A. Inflammatory brain damage in preterm newborns - dry numbers, wet lab, and causal inferences. Early Hum Dev 2004; 79: 1-15.
94. Ellison VJ, Mocatta TJ, Winterbourn CC, Darlow BA, Volpe JJ, Inder TE. The relationship of CSF and plasma cytokine levels to cerebral white matter injury in the premature newborn. Pediatr Res 2005; 57 282-286.
95. Folkerth RD, Haynes RL, Borenstein NS, Belliveau RA, Trachtenberg F, Rosenberg PA et al. Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J Neuropathol Exp Neurol 2004; 63 990-999.
96. Back SA. Perinatal white matter injury: The changing spectrum of pathology and emerging insights into pathogenetic mechanisms. Ment Retard Dev Disabil Res Rev 2006; 12: 129-140.
97. Felderhoff-Mueser U, Taylor DL, Greenwood K, Kozma M, Stibenz D, Joashi UC et al. Fas/CD95/APO-1 can function as a death receptor for neuronal cells in vitro and in vivo and is upregulated following cerebral hypoxic-ischemic injury to the developing rat brain. Brain Pathol 2000; 10: 17-29.
98. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999; 11: 13-18.
99. Dammann O, Durum S, Leviton A. Do white cells matter in white matter damage? Trends Neurosci 2001; 24: 320-324.
100. Hagberg H, Mallard C. Effect of inflammation on central nervous system development and vulnerability. Curr Opin Neurol 2005; 18: 117-123.
101. Leviton A, Gressens P. Neuronal damage accompanies perinatal white-matter damage. Trends Neurosci 2007; 30: 473-478.
102. Matute C, Perez-Cerda F. Multiple sclerosis: Novel perspectives on newly forming lesions. Trends Neurosci 2005; 28: 173-175.
103. Waldman A, O'Connor E, Tennekoon G. Childhood multiple sclerosis: A review. Ment Retard Dev Disabil Res Rev 2006; 12: 147-156.
104. Aktas O, Prozorovski T, Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006; 12: 305-316.
105. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001; 24: 224-230.
106. Werner P, Pitt D, Raine CS. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-180.
107. Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol 2006; 180 50-62.
108. Niehaus A, Shi J, Grzenkowski M, Diers-Fenger M, Archelos J, Hartung HP et al. Patients with active relapsing-emitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination. Ann Neurol 2000; 48: 362-371.
109. Cid C, Alvarez-Cermeno JC, Salinas M, Alcazar A. Anti-heat shock protein 90 beta antibodies decrease pre-oligodendrocyte population in perinatal and adult cell cultures. Implications for remyelination in multiple sclerosis. J Neurochem 2005; 95: 349-360.
110. Kikutani H, Suzuki K, Kumanogoh A. Immune semaphorins: Increasing members and their diverse roles. Adv Immunol 2007; 93: 121-143.
111. Giraudon P, Vincent P, Vuaillat C, Verlaeten O, Cartier L, Marie-Cardine A et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol 2004; 172: 1246-1255.
112. Giraudon P, Vincent P, Vuaillat C. T-Cells in neuronal injury and repair - Semaphorins and related T-cell signals. Neuromol Med 2005; 7 207-216.
113. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci 2000; 20: 6404-6412.
114. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci 1998; 18: 601-609.
115. Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis. Cell Mol Life Sci 2007; 64: 50-65.
116. Mimault C, Giraud G, Courtois V, Cailloux F, Boire JY, Dastugue B et al. Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher disease: Duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease. Am J Hum Genet 1999; 65: 360-369.
117. Southwood C, Gow A. Molecular pathways of oligodendrocyte apoptosis revealed by mutations in the proteolipid protein gene. Microsc Res Tech 2001; 52: 700-708.
118. Schneider AM, Griffiths IR, Readhead C, Nave KA. Dominant-negative action of the jimpy mutation in mice complemented with an autosomal transgene for myelin proteolipid protein. Proc Natl Acad Sci USA 1995; 92: 4447-4451.
119. Beesley JS, Lavy L, Eraydin NB, Siman R, Grinspan JB. Caspase-3 activation in oligodendrocytes from the myelin-deficient rat. J Neurosci Res 2001; 64: 371-379.
120. Xu J, Chen SW, Ahmed SH, Chen H, Ku G, Goldberg MP et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21: RC118.
121. Zeng C, Lee JT, Chen H, Chen S, Hsu CY, Xu J. Amyloid-beta peptide enhances tumor necrosis factor-alpha-induced NOS through neutral sphingomyelinase/ceramide pathway in oligodendrocytes. J Neurochem 2005; 94: 703-712.
122. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG. Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. NeuroReport 2003; 14: 1429-1433.
123. Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: A literature review. Mol Psychiatry 2008; 13: 245-260.
124. Stewart DG, Davis KL. Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. Int Rev Neurobiol 2004; 59: 381-424.
125. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-4751.
126. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007; 10: 537-545.
127. Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia - primary factor in pathology or epiphenomenon? Schizophr Bull 2008; 34: 72-92.